Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe Meeting Abstract
| Authors: | Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; Antonioli, E.; Schjesvold, F.; Lysén, A.; Kotowsky, N.; Camadoo-O'Byrne, L.; Bitetti, J.; Mouro, J.; D'Estrubé, T.; Fry, M.; Byrne, J.; Vossen, C. |
| Abstract Title: | Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S277 |
| End Page: | S278 |
| Language: | English |
| ACCESSION: | WOS:001325737900483 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)02323-1 |
| Notes: | Meeting Abstract: P-421 -- Source: Wos |
